The Tobacco Tax and Trade Bureau quietly rejected the idea that vodka bottled and distributed by Secaucus, NJ-based Bellion reduced the negative effects of booze on one’s liver. The privately held company claimed in its petition to the TTB that a proprietary blend of three ingredients added to its vodka would lessen alcohol’s effects on the human liver. It sought to add the health claims to its label.
The blend of glycyrrhizin, mannitol and potassium sorbate was dubbed NTX by its maker, Indian technology company Chigurupati Technologies Private Ltd. Neither company sought to have NTX called a drug, which would have put it under rigorous Federal Drug Administration review. The TTB after conferring with the FDA denied the petition.
Published: June 7, 2017
